NYSE:DNA • US37611X2099
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GINKGO BIOWORKS HOLDINGS INC (DNA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-12 | BTIG | Maintains | Sell -> Sell |
| 2026-01-08 | TD Cowen | Maintains | Buy -> Buy |
| 2025-08-25 | BTIG | Maintains | Sell -> Sell |
| 2024-09-20 | TD Cowen | Maintains | Buy -> Buy |
| 2024-08-23 | BTIG | Maintains | Sell -> Sell |
| 2024-07-09 | Goldman Sachs | Maintains | Sell -> Sell |
| 2024-06-26 | BTIG | Maintains | Sell -> Sell |
| 2024-05-15 | BTIG | Downgrade | Neutral -> Sell |
| 2024-05-15 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-05-10 | William Blair | Downgrade | Market Perform -> Underperform |
| 2024-03-01 | TD Cowen | Maintains | Outperform -> Outperform |
| 2024-01-23 | Goldman Sachs | Maintains | Sell -> Sell |
| 2024-01-22 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-11-15 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-11-14 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-11-09 | BTIG | Downgrade | Buy -> Neutral |
| 2023-06-05 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-06-02 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2023-05-11 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-11-29 | Berenberg | Initiate | Buy |
| 2022-10-04 | Morgan Stanley | Initiate | Equal-Weight |
| 2022-08-16 | BTIG | Maintains | Buy |
| 2022-08-16 | Raymond James | Maintains | Outperform |
| 2022-06-16 | Jefferies | Maintains | Buy |
| 2022-05-18 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 251.455M -47.36% | 227.043M -9.71% | 170.155M -25.06% | 161.68M -4.98% | 159.52M -1.34% | 299.36M 87.66% | 372.79M 24.53% | 469.55M 25.96% | 601.05M 28.01% | 734.37M 22.18% | |
| EBITDA YoY % growth | -505.514M 76.16% | -420.29M 16.86% | -250.888M 40.31% | -109.338M 56.42% | -104.005M 4.88% | 40.4M 138.84% | 44.44M 10.00% | 59.59M 34.09% | 93.93M 57.63% | 153.52M 63.44% | |
| EBIT YoY % growth | -576.021M 73.37% | -483.31M 16.10% | -309.878M 35.88% | -310.07M -0.06% | -285.83M 7.82% | -253.51M 11.31% | -205.03M 19.12% | -140.39M 31.53% | -55.55M 60.43% | 19.19M 134.55% | |
| Operating Margin | -229.08% | -212.87% | -182.12% | -191.78% | -179.18% | -84.68% | -55.00% | -29.90% | -9.24% | 2.61% | |
| EPS YoY % growth | -18.80 61.79% | -8.94 52.45% | -5.64 36.91% | -3.73 33.92% | -3.06 17.89% | -3.21 -4.95% | -0.01 99.69% | 0.10 1,100.00% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.09 35.07% | -1.13 -2.84% | -1.17 19.20% | -1.27 9.74% |
| Revenue Q2Q % growth | 41.935M -13.21% | 40.814M -17.72% | 40.148M 3.38% | 38.683M 15.83% |
| EBITDA Q2Q % growth | -27.725M 59.96% | -25.033M 27.07% | -27.997M 34.72% | -28.735M -128.49% |
| EBIT Q2Q % growth | -73.326M 13.34% | -75.952M -15.99% | -78.78M 10.70% | -81.81M -14.31% |
All data in USD
11 analysts have analysed DNA and the average price target is 10.2 USD. This implies a price increase of 28.3% is expected in the next year compared to the current price of 7.95.
GINKGO BIOWORKS HOLDINGS INC (DNA) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of GINKGO BIOWORKS HOLDINGS INC (DNA) is -1.09 USD and the consensus revenue estimate is 41.94M USD.
The number of analysts covering GINKGO BIOWORKS HOLDINGS INC (DNA) is 11.